ReviewFrontiers in pharmacology2024
Research progress on antidepressant effects and mechanisms of berberine.
Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effectiveness and safety of commercial Chinese polyherbal preparations combined with menopausal hormone therapy for perimenopausal symptoms: a network meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2026Pooled it
- The effects of berberine on depressive symptoms: a systematic review and meta-analysis of preclinical studies.Frontiers in psychiatry · 2025Pooled it
- Phytochemicals regulate cancer metabolism through modulation of the AMPK/PGC-1α signaling pathway.BMC cancer · 2024Pooled it
- Phytochemicals encouraging neurotrophic pathways: brain-derived neurotrophic factors as molecular targets in depression.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Integrative Medicine for Patients with Diabetes and Mental Health Disorders: A Narrative Review.Current psychiatry reports · 2025Review
- MicroRNAs as Regulators of Neuroinflammation in Major Depressive Disorder.Depression and anxiety · 2025Review
- The potential value of the use of berberine in depression: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2025Article
- Berberine alleviates chronic pain-induced anxiety-like behaviors by inhibiting the activation of VLT-projecting cACC (Cg2) neurons.Communications biology · 2024Article
- Neuroprotective effect and preparation methods of berberine.Frontiers in pharmacology · 2024Review
- The therapeutic potential of traditional Chinese medicine in depression: focused on the modulation of neuroplasticity.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression, a global health problem with growing prevalence, brings serious impacts on the daily life of patients. However, the antidepressants currently used in clinical are not perfectly effective, which greatly reduces the compliance of patients. Berberine is a natural quaternary alkaloid which has been shown to have a variety of pharmacological effects, such as hypoglycemic, lipid-regulation, anti-cancer, antibacterial, anti-oxidation, anti-inflammatory, and antidepressant. This review summarizes the evidence of pharmacological applications of berberine in treating depression and elucidates the mechanisms of berberine regulating neurotransmitter levels, promoting the regeneration of hippocampal neurons, improving hypothalamic-pituitary-adrenal axis dysfunction, anti-oxidative stress, and suppressing inflammatory status in order to provide a reference for further research and clinical application of berberine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.